Market Intelligence, Clinical Progress, and High-Purity Reagents for Breast Cancer and Chemoresistance Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ABCC11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ABCC11 ECD-Fc / Full-Length Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ABCC11 Products |
| Gene Delivery | ABCC11 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Preserves native membrane conformation. |
View ABCC11 Products |
| Benchmark Ab | Anti-ABCC11 (Clone 5D3) Recombinant positive control for expression validation. |
View ABCC11 Products |
| Validator | ABCC11 siRNA Set For knockdown verification and specificity controls. |
View ABCC11 Products |
| Related Target A | ABCC1 (MRP1) Synergistic efflux pathway member; essential for counter-screening selectivity. |
View ABCC1 Products |
| Related Target B | ABCG2 (BCRP) Competing ABC transporter in cancer stem cells; selectivity panel requirement. |
View ABCG2 Products |
| Related Target C | ABCB1 (MDR1/P-gp) Classical multidrug resistance target; off-target liability assessment. |
View ABCB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Membrane Topology Integrity (Multi-TM domains) | Lentivirus-Mediated Stable Expression (HEK293 background) preserves native folding and glycosylation for functional efflux assays. |
| Subfamily Selectivity Screening (ABCC1-5) | Homolog Panel Proteins strictly verified by mass spec; Sequence identity confirmation for selectivity assays. |
| Cross-species Cyno/Mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity; Endotoxin controlled. |
| Functional Efflux Validation | Sequence-verified ORF Lentivirus for cell-based accumulation assays (Calcein-AM, Hoechst 33342). |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for expression normalization. |
| False Positives | Validated siRNA included for specificity checks in RNAi rescue experiments. |
Live ABCC11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
ABCC11 (ATP-binding cassette sub-family C member 11, also known as MRP8) has evolved from a pharmacogenetic marker associated with apocrine secretion (earwax type) to a legitimate oncology target. Genome-wide association studies (GWAS) and functional genomics now link ABCC11 variants to breast cancer risk, apocrine gland development, and potential chemoresistance mechanisms.
As a transporter potentially involved in cancer stem cell maintenance and multidrug resistance, the therapeutic strategy focuses on selective inhibition to resensitize tumors to chemotherapy (particularly taxanes and anthracyclines). The race for ABCC11 therapeutics is intensifying, with major players shifting focus from broad-spectrum ABC inhibitors to highly selective ABCC11 antagonists. As first-generation diagnostic antibodies reach clinical validation, the next wave of R&D is targeting combination therapies that exploit ABCC11 expression profiles for patient stratification.
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Emerging biotech, Academic labs | Breast Cancer, Chemoresistance reversal | Selectivity Assay (Need ABCC1-5 panel proteins); Functional efflux assay using Lentivirus-stable cells. |
| Diagnostic Antibodies | CDx developers | Patient Stratification (ABCC11-high tumors) | IHC-grade proteins; Cross-reactivity validation vs ABCG2/ABCC1. |
| siRNA/ASO | RNAi specialists | Triple-negative Breast Cancer | Validated siRNA controls; Lentivirus for stable knockdown rescue experiments. |